Drug developers can now tap into an array of new preclinical technologies including some that give them the ability to interrogate compounds in a broad biological context-a systems biology approach. In this issue, we profile four start-ups with technologies designed to predict drugs' efficacy: Champions Biotechnology, Cytox, Immuneering and Rhenovia.
The next hurdle pharma faces as it endeavors to limit the cost and time associated with its drug development failures is the headache of predictive efficacy. Emergent diagnostics/research tools companies are lining up for the opportunity to help, offering diversity both in approaches and in therapeutic areas.
In the 1980s, the majority of drugs that were tabled had poor pharmacokinetics, leading to a heavy pharma investment in...
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.
Joshi joins the parent company of Citeline, which houses flagship publications Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.
From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.
